Recent Advances in the Assessment of Depression
neuroscienceCME Multimedia SnackPremiere Date: Friday, January 15, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, January 15, 2017
Note: Credit Is No Longer Available
|Alan F. Schatzberg, MD
Kenneth T. Norris, Jr. Professor
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
|Charles B. Nemeroff, MD, PhD
Leonard M. Miller Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Clinical Director, Center on Aging
Chief of Psychiatry, Jackson Memorial Hospital
Chief of Psychiatry, University of Miami Hospital
Professor of Biochemistry and Molecular Biology
Leonard M. Miller School of Medicine
University of Miami
Major depressive disorder (MDD) is a common condition with a high rate of recurrence, chronicity, staggering economic burden, and the highest estimates of disability in people of working age.1 The disability and disease burden is often attributable to the fact that a significant portion of patients with MDD will not achieve remission with initial treatment.2 Despite these challenges, MDD can be effectively managed, particularly when the clinician and patient mutually define what remission means to the patient and work together towards achieving sustained remission. Recent advances in psychopharmacotherapy have given patients with MDD new hope and clinicians new options. Novel and emerging therapies have demonstrated improved remission with new receptor targets, adjunctive therapies, and new approaches to treatment. The goal for the treatment of MDD is sustained symptom remission with total functional recovery.
This neuroscienceCME Snack on MDD featuring expert faculty offers new perspectives on treating this pervasive disorder and highlights residual symptoms as a challenge to clinicians.
- Centers for Disease Control and Prevention [CDC]. Mental health basics. CDC Website. http://www.cdc.gov/mentalhealth/basics.htm. Updated July 2013. Accessed December 21, 2015.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer -term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.PMID: 17074942.
At the end of this CE activity, participants should be able to:
- Engage the patient to develop a treatment strategy that addresses the cognitive and residual symptoms of depression.
- Routinely administer symptom assessment tools with patients with MDD to monitor clinical change over time.
- Initiate a treatment plan that includes the latest pharmacotherapeutic options for the treatment of MDD.
Supported by an educational grant from Allergan, Inc.
Physicians, pharmacists, and other health care professionals with an interest in mood disorders.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.1 CEUs)
Universal Activity Number: 0376-0000-15-004-L01-P (live programs)
0376-0000-16-013-H01-P (recorded programs)
Activity Type: knowledge-based
Successful completion of this CE activity includes participating in the live or recorded activity, reviewing the course materials, and following the appropriate set of instructions below within 30 days of completion of the activity:
To complete your activity evaluation and post-test online, and print your certificate or statement of credit immediately (75% pass rate required), please visit
www.CMEOutfitters.com/20084(requires free account activation).
There is no fee for participation in this activity. The estimated time for completion is 90 minutes.
Questions? Please call 877.CME.PROS
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Schatzberg has disclosed that he received grants/research support from the Pritzker Foundation. He serves as a consultant to Lundbeck/Takeda Pharmaceuticals U.S.A., Inc.; Myriad Genetics, Inc.; Naurex Inc.; Neuronetics Inc.; One Carbon; and Pfizer Inc. He is a stockholder in Amnestix, Inc.; Cervel Neurotech, Inc.; Corcept Therapeutics; Merck & Co., Inc.; Pfizer Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. Other financial interests include American Psychiatric Association (Royalties) and Stanford University (Royalties).
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Bracket (Clintara); Gerson Lehrman Group, Inc. (GLG) Healthcare & Biomedical Council; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals, Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; Total Pain Solutions (TPS); and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara);Brain & Behavior Research Foundation (BBRF) (formerly National Alliance for Research on Schizophrenia and Depression [NARSAD]); Clintara; RiverMend Health, LLC; Skyland Trail; and Xhale, Inc. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); and GratitudeAmerica, Inc. He is a stockholder of AbbVie Inc,; Bracket (Clintara); Celgene Corporation; COPKO Health, Inc.; Seattle Genetics, Inc.; Titan Pharmaceuticals, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; Takeda Pharmaceuticals North America, Inc.; Xhale, Inc. Dr. Nemeroff has patients for method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Tony Graham, MD (peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Allergan, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).